Focused On-demand Library for F-box/LRR-repeat protein 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UKT7

UPID:

FBXL3_HUMAN

Alternative names:

F-box and leucine-rich repeat protein 3A; F-box/LRR-repeat protein 3A

Alternative UPACC:

Q9UKT7; B2RB04; Q9P122

Background:

F-box/LRR-repeat protein 3, also known as F-box and leucine-rich repeat protein 3A, plays a pivotal role in the regulation of circadian rhythms. It functions as a substrate-recognition component of the SCF(FBXL3) E3 ubiquitin ligase complex, crucial for the maintenance of circadian clock oscillation. This protein's activity involves the ubiquitination and subsequent degradation of CRY1 and CRY2, essential for circadian rhythm precision.

Therapeutic significance:

Understanding the role of F-box/LRR-repeat protein 3 could open doors to potential therapeutic strategies for Intellectual developmental disorder with short stature, facial anomalies, and speech defects. This disorder, linked to variants affecting the gene encoding this protein, highlights its significance in neurodevelopmental processes.